Results 101 to 110 of about 167,688 (127)

Bridging Biochemical and Clinical Disease Burden in Fabry Disease: A Comparative Analysis of Lyso-Gb3, MSSI, DS3, and FASTEX. [PDF]

Int J Mol Sci
Ozturk S, Akyol EMB.
europepmc   +1 more source

Clinical manifestations, diagnosis, and management of renal involvement in Fabry disease. [PDF]

Ren Fail
Guo W, Bi J, Ji P, Xie Y.
europepmc   +1 more source

Impact of Proteinuria on Renal Outcomes in the BALANCE Trial. [PDF]

Kidney Int Rep
Wallace EL, Wanner C, Piotti G, Lee D, Koulinska I, Chertkoff R, Warnock DG, BALANCE Study Group.   +7 more
europepmc   +1 more source

Therapeutic landscape of Fabry disease: advances and challenges from classical strategies to emerging therapies. [PDF]

Front Med (Lausanne)
Zhang M, Wang C.
europepmc   +1 more source

Clinical Efficacy and Real-World Effectiveness of Fabry Disease Treatments: A Systematic Literature Review. [PDF]

J Clin Med
Jovanovic A, Miller-Hodges E, Castriota F, Evuarherhe O, Ayodele O, Hughes D, Pintos-Morell G, Giugliani R, Feriozzi S, Siffel C.   +9 more
europepmc   +1 more source

Use of nonsteroidal mineralocorticoid receptor antagonist in chronic kidney disease: A case report of a patient with Fabry disease in his mid-20s. [PDF]

J Int Med Res
Tian GQ, Yang P, Liao ZC, Xiao W, Li J, Song B.   +5 more
europepmc   +1 more source

Progress and Challenges in the Treatment of Fabry Disease. [PDF]

BioDrugs
Lenders M, Menke ER, Brand E.
europepmc   +1 more source

Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature [PDF]

Genetics in Medicine, 2017
Background:In 2009, the agalsidase beta shortage resulted in switching to agalsidase alfa treatment for many Fabry disease patients, offering the unique opportunity to compare the effects of the two drugs.
Massimo Imbriaco, Dario Bruzzese, Eleonora Riccio   +2 more
exaly   +2 more sources